Timothy A. Springer Ph.D.
Net Worth
Last updated:
What is Timothy A. Springer Ph.D. net worth?
The estimated net worth of Dr. Timothy A. Springer Ph.D. is at least $210,000 as of 3 May 2023. He has received compensation worth at least $210,000 in Morphic Holding, Inc..
What is the salary of Timothy A. Springer Ph.D.?
Dr. Timothy A. Springer Ph.D. salary is $35,000 per year as Founder, Independent Director & Member of Scientific Advisory Board in Morphic Holding, Inc..
How old is Timothy A. Springer Ph.D.?
Dr. Timothy A. Springer Ph.D. is 77 years old, born in 1948.
What stocks does Timothy A. Springer Ph.D. currently own?
As insider, Dr. Timothy A. Springer Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Morphic Holding, Inc. (MORF) | Founder, Independent Director & Member of Scientific Advisory Board | 2,768,464 | $0 | $0 |
What does Morphic Holding, Inc. do?
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Timothy A. Springer Ph.D. insider trading
Morphic Holding, Inc.
Morphic Holding key executives
Morphic Holding, Inc. executives and other stock owners filed with the SEC:
- Dr. Marc Schegerin M.B.A., M.D. (49) Chief Financial Officer & Chief Operating Officer
- Dr. Praveen P. Tipirneni M.D. (57) Chief Executive Officer, Pres & Director
- Dr. Timothy A. Springer Ph.D. (77) Founder, Independent Director & Member of Scientific Advisory Board